Metheny Leland, Caimi Paolo, de Lima Marcos
Stem Cell Transplantation Program, University Hospitals Case Medical Center, Case Western Reserve University , Cleveland, OH , USA.
Front Oncol. 2013 Sep 17;3:238. doi: 10.3389/fonc.2013.00238.
Umbilical cord blood is an established source of hematopoietic stem cells for transplantation. It enjoys several advantages over bone marrow or peripheral blood, including increased tolerance for Human Leukocyte Antigen mismatches, decreased incidence of graft-versus-host disease, and easy availability. Unrelated cord blood does have limitations, however, especially in the treatment of adults. In the 24 years since the first umbilical cord blood transplant was performed, significant progress has been made, but delayed hematopoietic engraftment and increased treatment-related mortality remain obstacles to widespread use. Here we summarize the latest results of unrelated cord blood transplants, and review strategies under investigation to improve clinical outcomes.
脐带血是一种既定的用于移植的造血干细胞来源。与骨髓或外周血相比，它具有几个优势，包括对人类白细胞抗原不匹配的耐受性增加、移植物抗宿主病的发病率降低以及易于获取。然而，无关供者脐带血确实存在局限性，尤其是在成人治疗方面。自首次进行脐带血移植以来的24年里，已经取得了重大进展，但造血植入延迟和治疗相关死亡率增加仍然是广泛应用的障碍。在此，我们总结了无关供者脐带血移植的最新结果，并回顾了正在研究的改善临床结局的策略。
